RECRUITING

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.

Official Title

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Quick Facts

Study Start:2020-01-09
Study Completion:2026-10-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05011045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 years or older
  2. * Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma)
  3. * Proficient and capable of completing tests in English
  4. * Patients with claustrophobia are eligible if the claustrophobia is managed with medication
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Dustin M Silk
CONTACT
713-563-3090
dmdmsilk@mdanderson.orgsilk@mdanderson.org

Principal Investigator

Bouthaina S Dabaja
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • Bouthaina S Dabaja, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-01-09
Study Completion Date2026-10-31

Study Record Updates

Study Start Date2020-01-09
Study Completion Date2026-10-31

Terms related to this study

Additional Relevant MeSH Terms

  • Central Nervous System Lymphoma
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Leukemia
  • Lymphoma
  • Plasma Cell Myeloma
  • Secondary Central Nervous System Lymphoma